Search Result

Results for "

Somatostatin+Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (7) Bombesin Receptor (1) Drug Derivative (2) Endogenous Metabolite (1) Isotope-Labeled Compounds (4) Liposome (4) Opioid Receptor (2) Radionuclide-Drug Conjugates (RDCs) (9) Reference Standards (2) Somatostatin Receptor (68) Urotensin Receptor (1)
By Research Areas:	Cancer (39) Cardiovascular Disease (13) Endocrinology (26) Inflammation/Immunology (13) Metabolic Disease (13) Neurological Disease (27)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Pegylated Lipids (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-P0036

Octreotide Maximum Cited Publications 16 Publications Verification SMS 201-995	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) is a *somatostatin receptor* agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the *somatostatin receptor* and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-16381

Pasireotide 5+ Cited Publications SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P10920

DOTAMTATE	Drug Derivative	Cancer
DOTAMTATE is a somatostatin analogue. DOTAMTATE marked ²¹²Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a *somatostatin receptor* 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1335

CTAP 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and *somatostatin receptors*. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P5126

DOTA-LM3 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a *somatostatin receptor* (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-139347

Mazisotine LY3556050; CNTX-0290	Somatostatin Receptor	Neurological Disease
Mazisotine (CNTX-0290) is an orally active, non-opioid somatostatin receptor 4 (SSTR4) agonist with an EC₅₀ of 4.7 nM. Mazisotine exerts significant analgesic effects in various nociceptive (inflammatory, osteoarthritic) and neuropathic pain models. Mazisotine can be used for pain research .

HY-111615

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective **somatostatin receptor type 4 (SST4 receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST4 receptors*, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-16381A

Pasireotide acetate 2 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-102037

SSTR5 antagonist 1	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC₅₀s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .

HY-P1201

Cyclosomatostatin 1 Publications Verification	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of *somatostatin receptor* subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-108497

L-803087	Somatostatin Receptor	Neurological Disease Cancer
L-803087 is a potent and selective **somatostatin sst4 receptor agonist with a K_i** of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-P1206

CH 275 1 Publications Verification	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P5126A

DOTA-LM3 TFA 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a *somatostatin receptor* (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and *selective somatostatin (receptor) subtype 5 (SSTR5)* antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

HY-79135

Pasireotide ditrifluoroacetate 5+ Cited Publications SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-79136

Pasireotide L-aspartate salt 5+ Cited Publications SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC₅₀ value of 1.3 nM against sst2 when labeled with [ ¹¹¹In-DTPA], and an IC₅₀ value of 1.6 nM against sst2 when labeled with [ ⁹⁰Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with ¹⁷⁷Lu or ⁹⁰Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .

HY-108498

L-817818	Somatostatin Receptor	Endocrinology
L-817818 is a potent and subtype-selective agonist of the *somatostatin receptor. L-817818 provides a direct approach to defining somatostatin receptor* physiological functions

HY-P10758

Alkyne-βAG-TOCA	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-163317A

MMC(TMZ)-TOC TFA	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC TFA has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC TFA targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC TFA can be used for the research of cancer .

HY-142699

SSTR4 agonist 2	Somatostatin Receptor	Inflammation/Immunology
SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107) .

HY-P1335A

CTAP TFA 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and *somatostatin receptors*. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

HY-P0036A

Octreotide dihydrochloride SMS 201-995 dihydrochloride	Somatostatin Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) hydrochloride is a *somatostatin receptor* agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the *somatostatin receptors* which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-142701

SSTR4 agonist 4	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 4 is a somatostatin receptor 4 (SSTR4) agonist. SSTR4 agonist 4 functionally activates SSTR4. SSTR4 agonist 4 has the potential for the research of pain .

HY-P2022

Pentetreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with ¹¹¹In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .

HY-P0024A

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a *somatostatin receptor* antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-P1207

BIM 23052	Somatostatin Receptor	Neurological Disease
BIM 23052 is a somatostatin receptor 5 agonist. BIM 23052 can induce gastric emptying .

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared withOctreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-108768

Pasireotide pamoate 5+ Cited Publications SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-159825

Branosotine	Somatostatin Receptor	Endocrinology
Branosotine (compound 1-1) is a potent agonist of somatostatin receptor (SSTR2), with the EC₅₀ of ＜0.1 nM .

HY-P0036B

Octreotide pamoate SMS 201-995 pamoate	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) pamoate is a *somatostatin receptor* agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the *somatostatin receptors* which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P0036S4

Octreotide-d8 acetate SMS 201-995-d8 acetate	Isotope-Labeled Compounds	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide-d₈ (acetate) (SMS 201-995-d₈ (acetate)) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a *somatostatin receptor* agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the *somatostatin receptor* and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-164040

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

HY-160176

SSTR5 antagonist 6	Somatostatin Receptor	Metabolic Disease
SSTR5 antagonist 6 is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with an IC₅₀ of 24 nM. SSTR5 antagonist 6 can be used in the study of type 2 diabetes .

HY-177282

*SST1 receptor* antagonist-2**	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
SST1 receptor antagonist-2 (Example 2) is a piperazine derivative and a somatostatin receptor 1 (SST1) antagonist. SST1 receptor antagonist-2 can be used in the research of psychiatric diseases, neurodegenerative diseases, tumors, as well as vascular disorders and immunological diseases .

HY-172147

SSTR4 agonist 5	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 5 (Compound 5) is the orally active agonist for somatostatin receptor 4 (SSTR4) with an EC₅₀ of 0.228 nM. SSTR4 agonist 5 exhibits good stability in human/rat liver microsomes. SSTR4 agonist 5 inhibits mechanical hyperalgesia in rat models .

HY-120287

L-054522	Somatostatin Receptor	Endocrinology
L-054522 is an agonist for somatostatin receptor subtype 2 with K_d of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC₅₀=0.05 nM) and glucagon and insulin release from isolated mouse pancreatic islet cell (IC₅₀=0.05 nM and 12 nM) .

Cat. No.	Nombre del producto	Type

HY-172280C

DSPE-PEG3400-octreotide	Biochemical Assay Reagents
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .

HY-172280B

DSPE-PEG5000-octreotide	Biochemical Assay Reagents
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .

HY-172280A

DSPE-PEG2000-octreotide	Biochemical Assay Reagents
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .

HY-172280

DSPE-PEG1000-octreotide	Biochemical Assay Reagents
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .

Cat. No.	Nombre del producto	Target	Research Area

HY-P0036

Octreotide Maximum Cited Publications 16 Publications Verification SMS 201-995	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) is a *somatostatin receptor* agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the *somatostatin receptor* and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-16381

Pasireotide 5+ Cited Publications SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P10920

DOTAMTATE	Drug Derivative	Cancer
DOTAMTATE is a somatostatin analogue. DOTAMTATE marked ²¹²Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a *somatostatin receptor* 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1335

CTAP 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and *somatostatin receptors*. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P5126

DOTA-LM3 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a *somatostatin receptor* (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-111615

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective **somatostatin receptor type 4 (SST4 receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST4 receptors*, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-16381A

Pasireotide acetate 2 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P1201

Cyclosomatostatin 1 Publications Verification	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of *somatostatin receptor* subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1206

CH 275 1 Publications Verification	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P5126A

DOTA-LM3 TFA 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a *somatostatin receptor* (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

HY-79136

Pasireotide L-aspartate salt 5+ Cited Publications SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC₅₀ value of 1.3 nM against sst2 when labeled with [ ¹¹¹In-DTPA], and an IC₅₀ value of 1.6 nM against sst2 when labeled with [ ⁹⁰Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with ¹⁷⁷Lu or ⁹⁰Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .

HY-P10758

Alkyne-βAG-TOCA	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1335A

CTAP TFA 2 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and *somatostatin receptors*. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC₅₀ = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC₅₀ values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .

HY-P0036A

Octreotide dihydrochloride SMS 201-995 dihydrochloride	Somatostatin Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) hydrochloride is a *somatostatin receptor* agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide hydrochloride can bind to the *somatostatin receptors* which are mainly subtypes 2, 3 and 5. Octreotide hydrochloride increases Gi activity and reduces intracellular cAMP production. Octreotide hydrochloride has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P2022

Pentetreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with ¹¹¹In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .

HY-P0024A

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a *somatostatin receptor* antagonist with K_is of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-P1207

BIM 23052	Somatostatin Receptor	Neurological Disease
BIM 23052 is a somatostatin receptor 5 agonist. BIM 23052 can induce gastric emptying .

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared withOctreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-108768

Pasireotide pamoate 5+ Cited Publications SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P0036B

Octreotide pamoate SMS 201-995 pamoate	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) pamoate is a *somatostatin receptor* agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the *somatostatin receptors* which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P4100

Cyclic SSTR agonist octreotide	Somatostatin Receptor	Others
Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic *Somatostatin Receptor* SSTR agonist .

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P4957

Octreotide dimer (parallel)	Somatostatin Receptor	Others
Octreotide dimer parallel is a dimer parallel of Octreotide. Octreotide (HY-P0036) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1384

L803	Somatostatin Receptor	Neurological Disease
L803 is a selective Somatostatin Receptor Subtype 4 (SST4) agonist. L803 inhibits L-type calcium channel currents (I_Ca). L803 is promising for research of retinal ganglion cell (RGC) degenerative diseases (e.g., glaucoma) .

HY-175053

Pasireotide (aspartate) TFA SOM230 (aspartate) TFA	Somatostatin Receptor Apoptosis	Metabolic Disease
Pasireotide (aspartate) TFA, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at *somatostatin receptors* (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide (aspartate) TFA can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide (aspartate) TFA also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P11463

Des-threoninol-octreotide	Somatostatin Receptor	Metabolic Disease
Des-threoninol-octreotide (Compound 13) is a Somatostatin analog. Des-threoninol-octreotide inhibits cloned *somatostatin receptors* with IC₅₀ values of 13.62 nM, 10.63 nM, 10.95 nM for mSSTR2b, rSSTR5 and hSSTR5, respectively .

HY-P11655

NOTA-TATE	Somatostatin Receptor	Neurological Disease
NOTA-TATE is a somatostatin receptor 2 (SSTR2) binder. NOTA-TATE binds to SSTR2 to enable targeting of SSTR2-positive tumour cells for PET imaging. NOTA-TATE can be used for the research of neuroendocrine tumours .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

Recombinant Proteins Recommended:

Somatostatin Receptor

Species:	Human (3)
Tag:	GFP (1) His (1) Tag Free (1)
Source:	HEK293 (3)

Cat. No.	Compare	Nombre del producto	Species	Source	Image

HY-P704897

	SSTR2 Protein-VLP, Human (HEK293) SSTR2; somatostatin receptor 2; somatostatin receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
	SSTR2 Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

HY-P700430

	SSTR2 Protein-VLP, Human (HEK293, His) SSTR2; somatostatin receptor 2; somatostatin receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
	SSTR2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA, FACS. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P704898

	SSTR2 Protein-VLP, Human (HEK293, GFP) SSTR2; somatostatin receptor 2; somatostatin receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
	SSTR2 Protein-VLP, Human (HEK293, GFP) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto	Chemical Structure

HY-P0036S4

Octreotide-d8 acetate

Octreotide-d₈ (acetate) (SMS 201-995-d₈ (acetate)) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P0036S2

Octreotide-d8

Octreotide-d₈ (SMS 201-995-d₈) is deuterium labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P0036S3

Octreotide-13C9,15N

Octreotide- ¹³C₉, ¹⁵N (SMS 201-995- ¹³C₉, ¹⁵N) is ¹³C and ¹⁵N labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .

HY-P0036S

Octreotide-d8 TFA

Octreotide-d₈ (SMS 201-995-d₈) TFA is the deuterium labeled Octreotide TFA. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.

Host:	Mouse (2) Rabbit (6)
Reactivity:	Human (8) Rat (1) Mouse (1)
Application:	IHC-P (2) ICC/IF (1) WB (4) FC (3) ELISA (2)
Isotype:	IgG (6) IgG1 (2)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (4) Recombinant (4)
Modification:	Unmodified (5)

Cat. No.	Compare	Nombre del producto	Application	Reactivity	Image

HY-P84249

	Somatostatin Receptor 2 Antibody (YA3946)	FC, ELISA	Human
	Somatostatin Receptor 2 Antibody (YA3946) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P87450

	Somatostatin Receptor 1 Antibody (YA7137)	WB, ICC/IF	Human
	Somatostatin Receptor 1 Antibody (YA7137) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 1.

HY-P84249A

	Somatostatin Receptor 2 Antibody (YA3946)(PBS only) Somatostatin receptor type 2, SS-2-R, SS2-R, SS2R, SST2, SRIF-1, SSTR2	FC, ELISA	Human
	Somatostatin Receptor 2 Antibody (YA3946) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P81452

	Somatostatin Receptor 2 Antibody (YA1197) SSTR2; somatostatin receptor 2; SS 2 R; SS2R; SRIF 1; SS2 R	IHC-P	Human
	Somatostatin Receptor 2 Antibody (YA1197) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P81452A

	Somatostatin Receptor 2 Antibody (YA1197)(PBS only) SSTR2; somatostatin receptor 2; SS 2 R; SS2R; SRIF 1; SS2 R	IHC-P	Human
	Somatostatin Receptor 2 Antibody (YA1197) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 2.

HY-P83055

	Somatostatin Receptor 5 Antibody (YA2800) SSTR5; SS5R; Sstr5	WB, FC	Human, Mouse, Rat
	Somatostatin Receptor 5 Antibody (YA2800) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 5.

HY-P82287

	Somatostatin Receptor 3 Antibody (YA2032) SS3R; SS3-R; SS-3-R; SSR-28	WB	Human
	Somatostatin Receptor 3 Antibody (YA2032) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 3.

HY-P82287A

	Somatostatin Receptor 3 Antibody (YA2032)(PBS only) SS3R; SS3-R; SS-3-R; SSR-28	WB	Human
	Somatostatin Receptor 3 Antibody (YA2032) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Somatostatin Receptor 3.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto		Classification

HY-P10758

Alkyne-βAG-TOCA		Alkynes
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Cat. No.	Nombre del producto		Classification

HY-172280C

DSPE-PEG3400-octreotide		Pegylated Lipids
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .

HY-172280B

DSPE-PEG5000-octreotide		Pegylated Lipids
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .

HY-172280A

DSPE-PEG2000-octreotide		Pegylated Lipids
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .

HY-172280

DSPE-PEG1000-octreotide		Pegylated Lipids
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: